View Single Post
Old 03-23-2006, 12:10 PM   #2
Christine MH-UK
Senior Member
 
Join Date: Sep 2005
Posts: 414
More on it from the New Scientist

http://www.newscientist.com/article/...al-horror.html

Apparently the drug was much less selective than other monoclonal antibodies.

Ironically, this news story seems to have made healthy, young men in Britain more interested in participating in trials because it has highlighted that they pay well and usually don't have much effect on volunteers.

Perhaps drugs companies should test such powerful drugs like they do cancer drugs: the first human trials only happen in someone with the disease who has exhausted other treatments and only one person at a time gets the treatment, at least at the start of the trial.
Christine MH-UK is offline   Reply With Quote